Back to search

University of Crete (UOC)

Μελέτη της επίδρασης του trastuzumab (herceptin) σε κυκλοφορούντα CK-19 mRNA θετικά κύτταρα, στο αίμα και το μυελό των οστών, ασθενών με καρκίνο του μαστού

Abstract

dc:description

Many investigators have shown that by using either monoclonal antibodies against molecules expressed on epithelial but not on mesenchymal cells, or molecular biology techniques, occult tumor cells can be detected in the bone marrow and/or the peripheral blood of patients with early and metastatic breast cancer. Moreover, prospective studies in patients with early stage breast cancer have shown that the detection of disseminated occult tumor cells in the bone marrow or the peripheral blood is an independent adverse prognostic factor associated with decreased disease-free survival (DFS) and overall survival (OS). In many patients (>50%), DTCs/CTCs are not killed by the administration of chemotherapeutic agents. Furthermore, the detection of micrometastatic cells after the administration of chemotherapy is associated with an increased risk of relapse and reduced survival. Although the HER2 receptor is overexpressed in 25-30% of the primary breast carcinomas, the overexpression of the receptor in CTCs/DTCs is >60% independently of HER2 expression on the primary tumor. The expression of HER2 on CTCs/DTCs is an independent prognostic factor associated with increased risk of relapse and reduced survival. Therefore, HER2 receptor could represent a suitable target for micrometastatic cells' elimination. In the first part of this study, we investigated the effectiveness of the anti-HER2 monoclonal antibody trastuzumab (Herceptin) to target the chemo resistant occult tumor cells in the peripheral blood and bone marrow of patients with breast cancer. For the detection of these cells, we used a nested RT-PCR and a real-time RT-PCR assay specific for cytokeratin-19 (CK-19) messenger RNA (mRNA). After trastuzumab infusions, overall 28 of 30 (93%) patients became CK19mRNA negative by nested RT-PCR and 20 of 30 (67%) by real-time RT-PCR. Since trastuzumab's administration effectively eliminates chemo-resistant CTCs, in the second part of this study we investigated the effect of trastuzumab on patients' clinical outcome. 75 patients with early HER2-negative breast cancer and detectable CK19mRNA-positive CTCs before and after adjuvant chemotherapy were randomized to receive either trastuzumab or observation. CK19 mRNA-positive CTCs were detected by RT-PCR and double-stained CK positive/HER2-positive cells by immunofluorescence. The primary end point was the 3-year disease-free survival (DFS) rate. After trastuzumab administration, 72% of the women in the trastuzumab arm became CK19mRNA-negative compared with 26% in the observation arm (P = 0.001). After a median follow-up time of 67.2 months, 4 (11%) and 15 (38%) relapses were observed in the trastuzumab and observation arm, respectively (P = 0.008). The median DFS was also significantly higher for the trastuzumab-treated patients (P = 0.008). Our results demonstrate that treatment with secondary adjuvant trastuzumab resulted in a significantly reduced probability of disease relapse and increased disease-free interval compared with patients receiving only standard treatment. A larger, multicenter, prospective randomized clinical trial is required to confirmthese findings.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2012

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bozionelou, Vasiliki
  • Μποζιονέλου, Βασιλική

Subjects

dc:subject × 23

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/29123

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bozionelou, Vasiliki; Μποζιονέλου, Βασιλική. Μελέτη της επίδρασης του trastuzumab (herceptin) σε κυκλοφορούντα CK-19 mRNA θετικά κύτταρα, στο αίμα και το μυελό των οστών, ασθενών με καρκίνο του μαστού. University of Crete (UOC), 2012. http://hdl.handle.net/10442/hedi/29123